ReviewClinical medicine (London, England)2026
Medication non-adherence and apparent treatment-resistant hypertension.
Review in Clinical medicine (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epidemiological Trends in Mortality From Acute Myocardial Infarction With Essential and Secondary Hypertension: CDC WONDER Database Analysis, 2000-2024.Clinical cardiology · 2026Review
- Hypertension: A common, yet poorly managed condition. What can we do better?Clinical medicine (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medication adherence refers to the extent to which a person's medication-taking behaviour corresponds with agreed recommendations from their clinician. Research shows that more than one-third of patients are non-adherent to their prescribed medications. Non-adherence is particularly significant in hypertension, as it complicates chronic disease management and may result in apparent treatment-resistant hypertension (aTRH), in which blood pressure remains uncontrolled despite appropriate pharmacological therapy and lifestyle measures. It is therefore important to assess adherence routinely, as non-adherence is one of the leading causes of aTRH. This article outlines a practical approach to recognising and assessing non-adherence using objective chemical adherence testing, and to managing medication non-adherence through non-judgemental, patient-centred discussion. Identifying non-adherence is vital, as failure to do so may lead to unnecessary treatment escalation, inappropriate investigations and avoidable healthcare costs, while addressing it can support and improve patient-centred outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.